| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8750753 | Respiratory Investigation | 2018 | 7 Pages |
Abstract
In elderly patients with previously untreated advanced NSCLC, a 2-week S-1 monotherapy treatment, tailored to both the Ccr and BSA, with a 1-week interval was well tolerated and demonstrated promising efficacy. This study was registered at the University Hospital Medical Information Network (UMIN) Center (ID: UMIN000002035), Japan.
Keywords
QLQ-C30S-1DCRULNQOLVASMSTCCRCTCAEEGFRALTQuality of lifeBSAPFsASTAspartate aminotransferaseAlanine aminotransferaseALKprogression-free survivaloverall survivalstable diseaseprogressive diseaseRECISTmedian survival timeElderlyLung cancerNSCLCNon-small cell lung cancerbody surface areaChemotherapyconfidence intervalAnaplastic lymphoma kinaseResponse Evaluation Criteria in Solid TumorsCommon Terminology Criteria for Adverse Eventsvisual analogue scalepatient-reported outcomeResponse rateDisease control ratePROPerformance statusPartial responsecomplete responseCreatinine clearanceEpidermal growth factor receptor
Related Topics
Life Sciences
Immunology and Microbiology
Immunology and Microbiology (General)
Authors
Hisatsugu Goto, Yoshio Okano, Hisanori Machida, Nobuo Hatakeyama, Fumitaka Ogushi, Takashi Haku, Takanori Kanematsu, Tomoyuki Urata, Soji Kakiuchi, Masaki Hanibuchi, Saburo Sone, Yasuhiko Nishioka,